Achieve Life Sciences, Inc. (QUIT)

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.

Ticker
QUIT
Exchange
Nasdaq
Sector
Healthcare
Industry
Biotechnology
Market cap
$649.88M
52-week range
$2.62 - $8.64

Valuation

Share price
$5.92 (close of Nov 18, 2026)
P/E (TTM)
-4.32x
Price to book
3.60x
Price to free cash flow
-14.74x
Enterprise value
$462.43M
Book value per share
$1.65

Price performance

PeriodChange
1 day-3.27%
5 days-8.22%
1 month-7.21%
3 months-21.28%
6 months+24.11%
Year to date+19.11%
1 year+36.72%
3 years+11.70%
5 years-21.17%
10 years-99.45%
All time-100.00%

Profitability and growth

Return on equity
-253.96%
Return on invested capital
-147.59%*
Return on assets
-130.77%
Return on capital employed
-164.57%*

* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.

Cash flow and balance sheet

Free cash flow yield (TTM)
-6.79%
Current ratio
10.49x
Net debt to EBITDA
1.70x

Latest reported year

Period end
Dec 31, 2025
Fiscal year
2025
EBITDA
-$53.60M
Net income
-$54.65M
Earnings per share
$-1.25
Interest expense
$819.00K
Shares outstanding
43.59M

Income statement by year

Period endNet incomeEPS
2025-12-31-$54.65M-$1.25
2024-12-31-$39.83M-$1.24
2023-12-31-$29.82M-$1.50
2022-12-31-$42.35M-$4.00
2021-12-31-$33.15M-$4.08
2020-12-31-$14.73M-$5.42
2019-12-31-$16.39M-$39.76
2018-12-31-$12.69M-$72.29
2017-12-31-$10.58M-$441.40
2016-12-31-$1.23M-$11,625.00

Margins and returns by year

Period endReturn on equityReturn on capital
2025-12-31-253.96%-147.59%*
2024-12-31-190.57%-122.00%*
2023-12-31--176.42%*
2022-12-31--165.55%*
2021-12-31-118.22%-77.03%*
2020-12-31-39.51%-39.33%*
2019-12-31-90.83%-89.05%*
2018-12-31-80.29%-80.17%*
2017-12-31-66.97%-86.28%*
2016-12-31-202.30%-284.92%*

* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.

Cash and debt by year

Period endCashDebt
2025-12-31$36.40M$11.19M
2024-12-31$34.40M$9.84M
2023-12-31$15.55M-
2022-12-31$24.77M-
2021-12-31$43.02M$14.92M
2020-12-31$35.85M-
2019-12-31$16.70M-
2018-12-31$14.60M-
2017-12-31$5.28M-
2016-12-31$25.50M-

Free cash flow by year

Period endFree cash flowStock-based compensation
2025-12-31-$49.47M$8.76M
2024-12-31-$29.77M$5.33M
2023-12-31-$24.50M$3.44M
2022-12-31-$37.57M$3.27M
2021-12-31-$29.44M$2.19M
2020-12-31-$13.49M$1.29M
2019-12-31-$15.27M$1.20M
2018-12-31-$10.67M$854.00K
2017-12-31-$9.11M$348.00K
2016-12-31-$248.00K$1.65M

Investor relations

Next earnings report

Next confirmed report
Nov 19, 2026
Consensus EPS estimate
$-0.19

Filings and sources

Company website
achievelifesciences.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Insmed Inc (INSM) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades